MYLK-AS1 promoted HCC tumor angiogenesis and cell proliferation in vitro and in vivo by directly targeting miR-424-5p to upregulate E2F7 and activate VEGFR-2 signaling, consequently promoting the HCC progression. The gene discussed is E2F7; the disease is neoplasm.